US20080233155A1 - Compositions For Antigen-Specific Induction of Tolerance - Google Patents
Compositions For Antigen-Specific Induction of Tolerance Download PDFInfo
- Publication number
- US20080233155A1 US20080233155A1 US11/914,815 US91481506A US2008233155A1 US 20080233155 A1 US20080233155 A1 US 20080233155A1 US 91481506 A US91481506 A US 91481506A US 2008233155 A1 US2008233155 A1 US 2008233155A1
- Authority
- US
- United States
- Prior art keywords
- genus
- protein allergen
- antigen
- kit
- allergen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 230000006698 induction Effects 0.000 title claims 2
- 102000036639 antigens Human genes 0.000 claims abstract description 89
- 108091007433 antigens Proteins 0.000 claims abstract description 89
- 239000000427 antigen Substances 0.000 claims abstract description 87
- 239000002671 adjuvant Substances 0.000 claims abstract description 72
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 42
- 241000894006 Bacteria Species 0.000 claims abstract description 34
- 239000011647 vitamin D3 Substances 0.000 claims abstract description 27
- 229940021056 vitamin d3 Drugs 0.000 claims abstract description 27
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 21
- 239000004310 lactic acid Substances 0.000 claims abstract description 21
- 239000003246 corticosteroid Substances 0.000 claims abstract description 20
- 230000002163 immunogen Effects 0.000 claims abstract description 20
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 19
- 235000005282 vitamin D3 Nutrition 0.000 claims abstract description 19
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims abstract description 19
- 239000002207 metabolite Substances 0.000 claims abstract description 16
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 12
- 239000003937 drug carrier Substances 0.000 claims abstract description 12
- 239000013566 allergen Substances 0.000 claims description 99
- 108090000623 proteins and genes Proteins 0.000 claims description 95
- 102000004169 proteins and genes Human genes 0.000 claims description 94
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 32
- 229960003957 dexamethasone Drugs 0.000 claims description 21
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 21
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 claims description 17
- 235000020964 calcitriol Nutrition 0.000 claims description 17
- 239000011612 calcitriol Substances 0.000 claims description 17
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 17
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 15
- 238000011260 co-administration Methods 0.000 claims description 14
- 206010020751 Hypersensitivity Diseases 0.000 claims description 13
- 230000007815 allergy Effects 0.000 claims description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims description 12
- 208000026935 allergic disease Diseases 0.000 claims description 12
- 102000003814 Interleukin-10 Human genes 0.000 claims description 11
- 108090000174 Interleukin-10 Proteins 0.000 claims description 11
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 10
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 10
- 210000003289 regulatory T cell Anatomy 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 8
- 241000186660 Lactobacillus Species 0.000 claims description 7
- 206010052779 Transplant rejections Diseases 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 229960002714 fluticasone Drugs 0.000 claims description 6
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 6
- 229940039696 lactobacillus Drugs 0.000 claims description 6
- 230000005867 T cell response Effects 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 241000721662 Juniperus Species 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 235000003932 Betula Nutrition 0.000 claims description 3
- 241000219429 Betula Species 0.000 claims description 3
- 241000536435 Blomia <angiosperm> Species 0.000 claims description 3
- 244000281762 Chenopodium ambrosioides Species 0.000 claims description 3
- 235000000509 Chenopodium ambrosioides Nutrition 0.000 claims description 3
- 235000005490 Chenopodium botrys Nutrition 0.000 claims description 3
- 241000218692 Cryptomeria Species 0.000 claims description 3
- 241000209210 Dactylis Species 0.000 claims description 3
- 241000282324 Felis Species 0.000 claims description 3
- 240000006394 Sorghum bicolor Species 0.000 claims description 3
- 235000011684 Sorghum saccharatum Nutrition 0.000 claims description 3
- 230000001332 colony forming effect Effects 0.000 claims description 3
- 230000031261 interleukin-10 production Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 241000209136 Agropyron Species 0.000 claims description 2
- 241000743339 Agrostis Species 0.000 claims description 2
- 241000223600 Alternaria Species 0.000 claims description 2
- 241000743857 Anthoxanthum Species 0.000 claims description 2
- 241000508787 Arrhenatherum Species 0.000 claims description 2
- 235000003826 Artemisia Nutrition 0.000 claims description 2
- 240000006891 Artemisia vulgaris Species 0.000 claims description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 2
- 235000005781 Avena Nutrition 0.000 claims description 2
- 244000075850 Avena orientalis Species 0.000 claims description 2
- 241000219495 Betulaceae Species 0.000 claims description 2
- 241000238658 Blattella Species 0.000 claims description 2
- 241000282465 Canis Species 0.000 claims description 2
- 241000723437 Chamaecyparis Species 0.000 claims description 2
- 241000723198 Cupressus Species 0.000 claims description 2
- 108010055622 Dermatophagoides farinae antigen f 1 Proteins 0.000 claims description 2
- 108010082990 Dermatophagoides farinae antigen f 7 Proteins 0.000 claims description 2
- 108010061629 Dermatophagoides pteronyssinus antigen p 1 Proteins 0.000 claims description 2
- 108010061608 Dermatophagoides pteronyssinus antigen p 2 Proteins 0.000 claims description 2
- 108010061612 Dermatophagoides pteronyssinus antigen p 3 Proteins 0.000 claims description 2
- 108010061638 Dermatophagoides pteronyssinus antigen p 7 Proteins 0.000 claims description 2
- 241000234642 Festuca Species 0.000 claims description 2
- 241000744855 Holcus Species 0.000 claims description 2
- 241000795633 Olea <sea slug> Species 0.000 claims description 2
- 241001268782 Paspalum dilatatum Species 0.000 claims description 2
- 241000238661 Periplaneta Species 0.000 claims description 2
- 241000745991 Phalaris Species 0.000 claims description 2
- 241001127637 Plantago Species 0.000 claims description 2
- 241000219492 Quercus Species 0.000 claims description 2
- 241000209056 Secale Species 0.000 claims description 2
- 240000006694 Stellaria media Species 0.000 claims description 2
- 241000218636 Thuja Species 0.000 claims description 2
- 235000021307 Triticum Nutrition 0.000 claims description 2
- 241000209140 Triticum Species 0.000 claims description 2
- 235000009052 artemisia Nutrition 0.000 claims description 2
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 claims 4
- 239000011782 vitamin Substances 0.000 claims 4
- 230000006058 immune tolerance Effects 0.000 abstract 1
- 108010058846 Ovalbumin Proteins 0.000 description 59
- 229940092253 ovalbumin Drugs 0.000 description 59
- 235000018102 proteins Nutrition 0.000 description 46
- 241000699670 Mus sp. Species 0.000 description 36
- 206010070834 Sensitisation Diseases 0.000 description 18
- 230000008313 sensitization Effects 0.000 description 17
- 230000004043 responsiveness Effects 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 238000009169 immunotherapy Methods 0.000 description 9
- 238000007912 intraperitoneal administration Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 210000004989 spleen cell Anatomy 0.000 description 8
- 239000000443 aerosol Substances 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 5
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229910001679 gibbsite Inorganic materials 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000024664 tolerance induction Effects 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- -1 coatings Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 229960002329 methacholine Drugs 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000023750 transforming growth factor beta production Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 244000124209 Crocus sativus Species 0.000 description 2
- 241000238710 Dermatophagoides Species 0.000 description 2
- 101150085950 IL10 gene Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 description 2
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- IOUUIFSIQMVYKP-UHFFFAOYSA-N Tetradecyl acetate Chemical compound CCCCCCCCCCCCCCOC(C)=O IOUUIFSIQMVYKP-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000005745 host immune response Effects 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102100032378 Carboxypeptidase E Human genes 0.000 description 1
- 108010058255 Carboxypeptidase H Proteins 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 102000016680 Dioxygenases Human genes 0.000 description 1
- 108010028143 Dioxygenases Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 241000209082 Lolium Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000746981 Phleum Species 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 102000016202 Proteolipids Human genes 0.000 description 1
- 108010010974 Proteolipids Proteins 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 description 1
- 241001661641 Verrucosa Species 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960004154 diflorasone Drugs 0.000 description 1
- WXURHACBFYSXBI-XHIJKXOTSA-N diflorasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-XHIJKXOTSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229940115747 halobetasol Drugs 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- LEHFPXVYPMWYQD-XHIJKXOTSA-N ulobetasol Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]2(C)C[C@@H]1O LEHFPXVYPMWYQD-XHIJKXOTSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
Definitions
- the present invention relates to adjuvants for sublingual, perlingual or oral immunotherapy.
- SLIT Allergen-specific sublingual immunotherapy
- Immunostimulatory agents or adjuvants have been used for many years to improve the host immune responses to, for example, vaccines.
- a wide range of adjuvants can provoke potent immune responses to antigens but are not deprived of toxic effects. These include saponins complexed to membrane protein antigens (immune stimulating complexes), pluronic polymers with mineral oil, killed mycobacteria in mineral oil, Freund's complete adjuvant, bacterial products, such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as lipid A, and liposomes.
- MDP muramyl dipeptide
- LPS lipopolysaccharide
- Lactobacillus plantarum was tested for intranasal delivery of heterologous antigens (Grangette et al., (2001) Infection and Immunity 69(3) 1547-1553).
- Th1 and/or Th2 responses All these adjuvants have been used with the aim to trigger T-cell mediated immune effector mechanisms (so called Th1 and/or Th2 responses).
- the inventors have now identified adjuvants that elicit antigen-specific regulatory T cells when administered by sublingual, perlingual or oral route.
- T-cell mediated regulatory mechanisms inhibit the above mentioned Th1 and Th2 effector mechanisms, in particular by eliciting an increase in IL10 secretion by T cells.
- Such adjuvants are of great interest in immunotherapy of allergic, and other immune disorders.
- regulatory T cells are heterogeneous, and include both: (i) naturally occurring CD4+CD25+ T cells (ii) cells induced in the periphery following antigen exposure (e.g. Tr1 cells, Th3 cells, and CD8+ T R cells).
- the adjuvants identified by the inventors are a bacterium selected from a Bifidobacterium and a lactic acid bacterium, and a combination of a corticosteroid and vitamin D3 (or its metabolites, such as 1 ⁇ ,25-dihydroxyvitamin D3, or analogs).
- the inventors have notably shown that these adjuvants were liable to induce the secretion of IL10 by human T cells in vitro and that they could improve the clinical efficacy of specific immunotherapy in an animal model of asthma.
- a subject of the invention is thus an immunogenic composition for inducing antigen-specific tolerance for sublingual, perlingual or oral administration, comprising at least an antigen and at least an adjuvant that is;
- the invention further provides a kit comprising:
- adjuvants are useful for the preparation of an immunogenic composition for sublingual, perlingual or oral administration in association with at least an antigen, for inducing an antigen-specific tolerance, especially for eliciting or improving antigen-specific regulatory T cell responses, in particular by eliciting an increase in IL10 secretion by T cells.
- the immunogenic composition that comprises an antigen and such adjuvant is particularly useful for the preparation of a medicament for treating an allergy, an auto-immune disease, or for preventing graft rejection.
- the adjuvant is a bacterium selected from a Bifidobacterium and a lactic acid bacterium.
- the bacterium selected from a Bifidobacterium and a lactic acid bacterium is a probiotic.
- probiotic relates to bacteria which exert a beneficial effect on a host they are intended to be administered to, by improving the equilibrium of the intestinal flora of said host.
- Bifidobacteria include those belonging to the genus Bifidibacterium , such as Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium infantis and Bifidobacterium animalis.
- Lactic acid bacteria include those belonging to the genus Lactobacillus, Lactococcus or Streptococcus , such as Lactobacillus plantarum, Lactobacillus delbrueckii, Lactobacillus acidophilus, Lactobacillus fermentum, Lactobacillus casei, Lactobacillus rhamnosus, Lactococcus lactis and Streptococcus thermophilus.
- the adjuvant may further be a mixture of at least two bacteria selected from Bifidobacteria and a lactic acid bacteria, in particular at least two lactic acid bacteria, of different genus or species. It may also be one or several mutants thereof, selected for specific immunomodulatory properties.
- the bacteria selected from a Bifidobacterium and a lactic acid bacterium, in particular the lactic acid bacterium is liable to induce IL10 production by T cells.
- the lactic acid bacterium is a Lactobacillus , most preferably Lactobacillus plantarum.
- the bacteria selected from a Bifidobacterium and a lactic acid bacterium, in particular the lactic acid bacterium, may be present in the immunogenic composition of the invention at about 1.10 8 to 1.10 9 colony forming units (CFU)/ml, preferably about 5.10 8 to 1.10 9 CFU/ml.
- CFU colony forming units
- the adjuvant is a combination of a corticosteroid with vitamin D3 or any metabolite or analog of the latter.
- the adjuvant is a combination of (i) a corticosteroid and (ii) vitamin D3 or 1 ⁇ ,25-dihydroxyvitamin D3.
- the glucocorticoid used as an adjuvant may be of any type. It may be selected from the group consisting of cortisone, hydrocortisone, beclomethasone, flunisolide, prednisone, prednisolone, methylprednisolone, triamcinolone, deflazacort, betamethasone, dexamethasone, diflorasone, fluticasone, halobetasol, budesonide, clobetasol, fluocinolone, and triamcinolone, or any pharmaceutically acceptable salt thereof.
- it is dexamethasone or fluticasone. Most preferably it is dexamethasone.
- vitamin D3 means cholecalciferol. Its metabolites or analogs include 1 ⁇ ,25-dihydroxyvitamin D3 and any of cholecalciferol;
- a preferred combination is dexamethasone and 1 ⁇ ,25-dihydroxyvitamin D3.
- the combination of vitamin D3 or its metabolites or analogs, and corticosteroid may be present in the following proportions:
- the antigen may of any type. It can be a protein, a polypeptide or a peptide, a carbohydrate, a lipid, or a nucleic acid.
- Peptides having defined amino acid sequences and which comprise T cell epitopes may be identified for any protein antigen or autoantigen.
- One method includes dividing the protein antigen into non-overlapping, or overlapping peptides of desired lengths and synthesizing, purifying and testing those peptides to determine whether the peptides comprise at least one T cell epitope using any number of assays, (e.g. T cell proliferation assays, lymphokine secretion assays, and T cell non-responsiveness studies).
- an algorithm is used for predicting those peptides which are likely to comprise T cell epitopes and then synthesizing, purifying and testing the peptides predicted by the algorithm in T cell assays to determine if such predicted peptides cause T cell proliferation or lymphokine secretion, or T cell non-responsiveness and are therefore likely to contain T cell epitopes.
- the antigen is an allergen.
- An “allergen” is defined as a substance, usually a protein, which elicits the production of IgE antibodies in predisposed individuals. Similar definitions are presented in the following references: Clin. Exp. Allergy, No. 26, pp. 494-516 (1996); Mol. Biol. of Allergy and Immunology, ed. R. Bush, Immunology and Allergy Clinics of North American Series (March 1996).
- the antigen is a protein allergen, which means any amino acid chain likely to trigger an allergic response, including short peptides of about 6 to 20 aminoacids, polypeptides, or full proteins.
- the protein allergen is selected from the group consisting of a protein allergen of the genus Dermatophagoides ; a protein allergen of the genus Felis ; a protein allergen of the genus Ambrosia ; a protein allergen of the genus Lolium ; a protein allergen of the genus Cryptomeria ; a protein allergen of the genus Alternaria ; a protein allergen of the genus Alder ; a protein allergen of the genus Betula ; a protein allergen of the genus of Blomia ; a protein allergen of the genus Quercus ; a protein allergen of the genus Olea ; a protein allergen of the genus Artemisia ; a protein allergen of the genus Plantago ; a protein allergen of the genus Parietaria ; a protein allergen of the genus Canine ; a protein allergen of the genus of the
- Examples of various known protein allergens derived from some of the above-identified genus include: Betula ( verrucosa ) Bet v I; Bet v II; Blomia Blo t I; Blo t III; Blo t V; Blo t XII; Cynorhodon Cyn d I; Dermatophagoides ( pteronyssinus or farinae ) Der p I; Der p II; Der p III; Der p VII; Der f I; Der f II; Der f III; Der f VII; Felis ( domesticus ) Fel d I; Ambrosia ( artemiisfolia ) Amb a I.1; Amb a I.2; Amb a I.3; Amb a I.4; Amb a II; Lollium ( perenne ) Lol p I; Lot p II; Lol p III; Lot p IV; Lol p IX (Lol p V or
- autoimmune diseases such as Type I diabetes, multiple sclerosis, and rheumatoid arthritis are generally accepted as being the result of an antigen specific T cell mediated response against an antigen which in the case of autoimmune disease is an autoantigen, i.e. an antigen that belongs to the body's own tissue.
- an autoantigen i.e. an antigen that belongs to the body's own tissue.
- graft rejection where the antigen belongs to the graft tissue, possibly coming from another individual or even from another animal species.
- the antigen is involved in a autoimmune disease or graft rejection.
- autoantigens A number of antigens (i.e. autoantigens) have been found to cause symptoms in autoimmune diseases (i.e. autoantigens such as insulin; myelin basic protein; rh factor; acetylcholine receptors; thyroid cell receptors; basement membrane proteins; thyroid proteins, ICA-69 (PM-1); glutamic acid decarboxylase (64K or 65 K); proteolipid protein (PLP), myelin associated glycoprotein (MAG), Collagen (Type II), Heat Shock Protein and carboxypeptidase H) such as diabetes, rheumatoid arthritis, and multiple sclerosis.
- autoantigens such as insulin; myelin basic protein; rh factor; acetylcholine receptors; thyroid cell receptors; basement membrane proteins; thyroid proteins, ICA-69 (PM-1); glutamic acid decarboxylase (64K or 65 K); proteolipid protein (PLP), myelin associated glycoprotein (MAG), Collagen (Type II), Heat Shock Protein
- the antigen and the adjuvant as above defined are either combined in an immunogenic composition or are presented separately, for a co-administration.
- the immunogenic composition comprises at least an adjuvant as defined above, that is to say that one may also employ additional adjuvants.
- the antigen and the adjuvant are associated with a pharmaceutically acceptable carrier that is suitable for sublingual, perlingual (i.e. through the tongue mucosa) or oral administration.
- a pharmaceutically acceptable carrier that is suitable for sublingual, perlingual (i.e. through the tongue mucosa) or oral administration.
- the antigen and the adjuvant can also be co-administered in the form of separate compositions.
- the co-administration means either simultaneous or consecutive administration of said compositions.
- pharmaceutically acceptable carrier includes solvents, dispersion media, coatings, isotonic and absorption delaying agents, mucoadhesive excipients, and the like, that do not produce an adverse or other untoward reaction when administered to an animal, or a human, as appropriate.
- Preferred sublingual, perlingual or oral dosage forms include solid forms, adhesive tablets, biofilms or creams, ointments, powders, gels; and pastes.
- a preferred form is a tablet, e g., as those described in U.S. Pat. No. 5,244,663.
- the sublingual or perlingual dosage unit is manufactured to disintegrate rapidly.
- the time period for complete disintegration of the dosage unit is typically in the range of from about 10 seconds to about 30 minutes, and optimally is less than 5 minutes.
- Carriers may further include, but are not limited to disintegrants, binders, lubricants, flavoring, colorants, preservatives.
- Suitable disintegrants include dry starch, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, stearic monoglyceride, lactose, as well as cross-linked polyvinylpyrrolidones, such as crospovidone (e.g., PolyplasdoneTM.
- XL which may be obtained from GAF
- cross-linked carboxylic methylcelluloses such as croscarmelose (e.g., Ac-di-solTM, which may be obtained from FMC), alginic acid, and sodium carboxymethyl starches (e.g., ExplotabTM, which may be obtained from Edward Medell Co., Inc.), methylcellulose, agar bentonite and alginic acid.
- Binders if used, are those that enhance adhesion. Examples of such binders include, but are not limited to, starch, gelatin and sugars such as sucrose, dextrose, molasses, and lactose.
- Preferred lubricants are stearates and stearic acid.
- Lactose, mannitol, and croscarmelose are preferred excipients.
- the immunogenic composition is in a liquid form.
- composition can be administered as dry powder particles or as an atomized aqueous solution suspended in a carrier gas (e.g. air or N 2 ).
- a carrier gas e.g. air or N 2
- Preferred aerosol formulations may comprise for example, a physiologically-acceptable buffered saline solution containing between about 1 ⁇ g and about 300 ⁇ g of the antigens.
- aqueous suspensions and/or elixirs For the preparation of aqueous suspensions and/or elixirs, one may employ various sweetening or flavouring agents, colouring matter and, if so desired, emulsifying and/or suspending agents, together with such diluents as water, ethanol, propylene glycol, glycerine and various combinations thereof. Glycerine is preferred.
- the immunogenic composition is preferably administered to the patient under the tongue.
- the sublingual mucosa located on the underside of the tongue, facilitates capture of the antigen and adjuvant by Langerhans-like cells that migrate to draining lymph nodes to prime T lymphocytes.
- recombinant Bet v I protein allergen has been formulated as a tablet for sublingual administration.
- the composition When it is in liquid form, the composition can be administered under the tongue by placing one or more drops underneath the tongue or by spraying the underside of the tongue with a preselected volume of the liquid composition.
- the administered volume is less than about 1 ml.
- a route of administration of particular interest is to keep the composition under the tongue a few minutes, e.g. about 2 minutes, before swallowing it.
- the present invention further provides a kit comprising:
- Another subject of the invention is a kit comprising:
- a further subject of the invention is a kit comprising:
- the antigen and the adjuvant are co-administered in separate compositions or provided as a kit, they can be in different types of carriers, both suitable for sublingual, perlingual or co-administration.
- the antigen may be in the form of a solid composition, while the adjuvant is in a liquid composition.
- the immunogenic compositions that combine an antigen with the adjuvant can be used as a vaccine, or in a therapeutic or prophylactic treatment regimen for the prevention of, or delay in, the onset of disease symptoms caused by an offending antigen or results in reduction, progression, or alleviation of symptoms caused by an offending antigen, i.e. down regulation of an antigen specific immune response.
- the kits disclosed herein are similarly useful.
- Immunotherapy of allergies generally comprises desensitization or hyposensitisation, which is a treatment consisting in administering to the patient progressively increasing doses of the allergen(s) to which the patient has developed or is likely to develop a sensitivity.
- a method for preventing or treating an allergy comprises administering to a subject in need thereof an antigen and the adjuvant as described above, e.g. in the form of an immunogenic composition, wherein the antigen is an allergen.
- a method for treating a autoimmune disease comprises administering to a subject in need thereof an antigen and the adjuvant as described above, e.g. in the form of an immunogenic composition, e, wherein the antigen is involved in the autoimmune disease.
- an antigen and the adjuvant as described above, e.g. in the form of an immunogenic composition, e, wherein the antigen is involved in the autoimmune disease.
- Non limiting examples include rheumatoid arthritis, multiple sclerosis, endocrine ophthalmopathy, uveoretinitis, Type 1 diabetes, systemic lupus erythematosus sclerodermia, myasthenia gravis, Grave's disease, glomerulonephritis, autoimmune hematological disorder, autoimmune inflammatory bowel disease, and Crohn's disease.
- the antigen and the adjuvant as described above are also useful in the treatment of recipients of tissue or organ transplants to reduce host-induced allograft rejection.
- a method for preventing a graft rejection comprises administering to a subject in need thereof an antigen and the adjuvant as described above, e.g. in the form of an immunogenic composition, wherein the antigen belongs to the graft tissue and is likely to cause graft rejection.
- the subject is preferably a human, regardless of the age, sex, and condition. It may also be any other mammal, including pets such as cats or dogs.
- FIG. 1 Experimental design
- Sensitization was performed by two intraperitoneal (i.p.) injections in 14 days interval with 10 ⁇ g ovalbumin (OVA) or phosphate buffer saline (PBS) (control) adsorbed to 2 mg Al(OH) 3 . The sensitization was followed by a 20 min aerosol challenge with 1% w/v OVA on 5 consecutive days. Blood samples (bleeding) were taken in order to perform the anti-OVA antibody titration. Measurements of airway responsiveness were performed by whole body plethysmography. After sacrifice of mice, spleen cells and lung were isolated for cytokine analysis and inflammation detection respectively.
- OVA ovalbumin
- PBS phosphate buffer saline
- mice For tolerance induction in a therapeutic model, sensitized mice were sublingually treated with PBS (control), OVA or OVA plus adjuvant every week, twice a week, during 2 months at a concentration of 500 ⁇ g. Blood samples (bleeding) were taken for humoral response analysis. Measurements of airway responsiveness were performed by whole body plethysmography. After sacrifice of mice, spleen and lung were removed for in vitro cytokine assays and inflammation analysis respectively.
- PBS control
- OVA or OVA plus adjuvant every week, twice a week, during 2 months at a concentration of 500 ⁇ g.
- Blood samples were taken for humoral response analysis. Measurements of airway responsiveness were performed by whole body plethysmography. After sacrifice of mice, spleen and lung were removed for in vitro cytokine assays and inflammation analysis respectively.
- mice were sublingually treated with PBS, OVA or OVA plus adjuvant every week, twice a week, during 1 month at a concentration of 500 ⁇ g.
- Sensitization was performed by two intraperitoneal (i.p.) injections in 14 days interval with 10 ⁇ g ovalbumin (OVA) or phosphate buffer saline (PBS) (control) adsorbed to 2 mg Al(OH)3. The sensitization was followed by a 20 min aerosol challenge with 1% w/v OVA on 5 consecutive days. Blood samples (bleeding) were taken for humoral response analysis. Measurements of airway responsiveness were performed by whole body plethysmography. After sacrifice of mice, spleen and lung were removed for in vitro cytokine assays and inflammation analysis respectively.
- FIG. 2 Humoral, cellular, respiratory responses, and inflammation after sensitization
- OVA-specific IgG1 and IgG2a (dilution 1/100) antibody levels were measured in sera from 4 mice sensitized with OVA.
- OVA-specific IgE (dilution 1/10) antibody level was measured in sera from 3 mice sensitized with OVA.
- IFN- ⁇ , IL-5 and IL10 levels in spleen cell of mice sensitized with OVA were measured by Elispot.
- E Representative lung sections obtained 48 h after the last challenge. Paraffin tissue sections were stained with HES (Hematoxylin, eosin, safran). One arrow (top) indicates bronchial mucus secretion and the other arrow (bottom) indicates specific cellular infiltration.
- HES Hematoxylin, eosin, safran
- FIG. 3 Airway responsiveness after tolerization
- mice sensitized with OVA and tolerized with PBS mice sensitized with OVA and tolerized with OVA and mice sensitized with OVA and tolerized with OVA+dexamethasone (Dex)+1 ⁇ ,25-dihydroxyvitamin D3 (vitD3) (panel A) or OVA+ L. plantarum (panel B) by measurement of Penh value in response to methacholine (50 mg/ml). Four to eight mice per group were displayed (horizontal bar median).
- FIG. 4 TGF- ⁇ production after tolerization
- Adjuvants inducing IL10 gene expression by human T cells in vitro were mixed with ovalbumin and administered sublingually to Balb/c mice sensitized to ovalbumin.
- ovalbumin alone or untreated animals
- each of those adjuvants could enhance the clinical efficacy of the vaccine (based on improvement of the respiratory function).
- Clinical improvement was correlated with an increase in ovalbumin-specific TGF ⁇ producing T lymphocytes in the spleen (i.e. T cells with a regulatory profile, subtype Tr1 or Th3).
- mice Six-week-old female BALB/c mice were purchased from Charles River (L'Arbresle, France) and maintained on an ovalbumin-free diet. Each experimental group consisted of two to eight mice. The international levels of ethical standards for the use of animals were applied.
- Culture medium for spleen cell consisted of RPMI 1640 containing 10% fetal calf serum and 1% L-glutamine (all from Invitrogen, France).
- Ovalbumin (OVA, Garde V) was purchased from Sigma Chemicals.
- Phosphate-buffer saline (PBS) and alum were purchased from Invitrogen (France) and Pierce (Rockford, Ill.), respectively.
- LAB lactic acid bacteria
- BALB/c mice Macrobiologics, Inc., Saint Cloud mice
- CFU colony forming units
- Sensitization was performed by two intraperitoneal (i.p.) injections in 14 days interval with 10 ⁇ g OVA adsorbed to 2 mg Al(OH) 3 in a total volume of 100 ⁇ l. The sensitization was followed by a 20 min aerosol challenge with 1% w/v OVA on 5 consecutive days with an aerosol delivery system (Buxco Europe; Ltd, UK). Control animals were sham treated with sterile PBS.
- sensitized mice were sublingually treated with OVA or OVA plus adjuvant every week, twice a week, during 2 months at a concentration of 500 ⁇ g (20 ⁇ l).
- Control mice were sensitized with OVA followed by sham tolerization with PBS.
- mice were sublingualy treated with PBS, OVA or OVA plus adjuvant every week, twice a week, during 1 month at a concentration of 500 ⁇ g.
- Sensitization was performed by two intraperitoneal. (i.p.) injections in 14 days interval with 10 ⁇ g ovalbumin (OVA) or phosphate buffer saline (PBS) (control) adsorbed to 2 mg Al(OH) 3 .
- OVA ovalbumin
- PBS phosphate buffer saline
- mouse IgE antibodies (Bethyl laboratories) were coated onto Elisa plates. The mouse anti-serum was applied and OVA-digoxigenin (dilution 1/20, Roche) plus HRPO-conjugated rabbit anti-digoxigenin (dilution 1/1000, Roche) were used for detection. An ABTS substrate was added (Roche), the reaction stopped and the OD read using an ELISA reader at 405 nm.
- TGF- ⁇ Dosage of TGF- ⁇ from supernatants of spleen cell cultures was performed with an ELISA kit (R&D systems).
- mice were killed by cervical dislocation. Lung were isolated and embedded in paraffin. Micrometer paraffin sections were stained with HES (hematoxylin, eosin, safran).
- DC Dendritic cells
- Human in vitro model consisting in coculture of human preated DC with allogenic T cells have been used to select IL10-inducing adjuvants. Briefly, human DC were treated with adjuvants. After 24 h, DC were washed and cultured with allogenic na ⁇ ve CD4+ T cells. After 24 h to 5 days, gene expression in human T cells was assessed by quantitative PCR.
- Lactobacillus plantarum and 1 ⁇ ,25-dihydroxyvitamin D3 in combination with dexamethasone have been shown liable to induce IL10 gene expression by human T cells in vitro (Table 1).
- mice immunized i.p. with OVA absorbed to Al(OH) 3 and subsequently exposed to an OVA solution via aerosol, were analysed for their humoral, cellular, respiratory responses and inflammation.
- the sensitization procedure has been shown to induce OVA-specific IgG1 and IgE, but little IgG2a antibodies in serum ( FIGS. 2A and 2B ).
- spleen cells from the OVA-sensitization mice displayed strong Th2 profile in response to OVA ( FIG. 2C ).
- OVA-sensitized mice present airway hyperresponsiveness to methacholine when compared to PBS-treated mice ( FIG. 2D ).
- the sensitization protocol has been shown to induce specific cellular infiltration of the lung and bronchial mucus secretion ( FIG. 2E ).
- the inventors After having sensitized the mice, the inventors have tested different protocol of tolerization and particularly the capacity of candidate adjuvants to upregulate antigen-specific regulatory T cell responses and accelerate the tolerance induction by sublingual way. Lactobacillus plantarum and 1 ⁇ ,25-dihydroxyvitamin D3 in combination with dexamethasone have been tested as adjuvants for upregulation of antigen-specific regulatory T cell responses.
- TGF- ⁇ production was enhanced in supernatant of spleen cell cultures of mice treated with OVA and L. plantarum ( FIG. 4A ) or 1 ⁇ ,25-dihydroxyvitamin D3 plus dexamethasone ( FIG. 4B ) compared to PBS-treated mice or animals treated with OVA alone.
- Sublingual desensitization is also tested in a murine prophylactic model of asthma. Briefly, Balb/c mice are sublingually administered with an adjuvant to be tested (1 ⁇ ,25-dihydroxyvitamin D3+dexamethasone) in association with an antigen (OVA) (500 ⁇ g) 2 times per week during 4 weeks prior to being sensitized and challenged by OVA.
- an adjuvant to be tested (1 ⁇ ,25-dihydroxyvitamin D3+dexamethasone) in association with an antigen (OVA) (500 ⁇ g) 2 times per week during 4 weeks prior to being sensitized and challenged by OVA.
- OVA antigen
- mice with OVA+adjuvant according to the invention are liable to induce a reduction of airway responsiveness following subsequent sensitization.
- the adjuvants according to the invention are tested in murine model of sensitization either to birch pollen or house dust mite and also seem promising for preventing or treating allergies with these allergens.
Abstract
Description
- The present invention relates to adjuvants for sublingual, perlingual or oral immunotherapy.
- The sublingual route has been recently explored for antigen administration in a variety of conditions, especially in the field of immunotherapy of allergy. Allergen-specific sublingual immunotherapy (SLIT) indeed represents a safe and efficient non invasive alternative to subcutaneous immunotherapy (see e.g. Bahceciler et al., (2005) Int. Arch. Allergy Immunol., 136:287-294). During SLIT, the allergen is captured within the oral mucosa by Langerhans-like dendritic cells expressing high affinity IgE receptors, producing IL10 (interleukin 10) and TGFβ and upregulating the indoleamine dioxygenase (IDO), suggesting that such cells are prone to induce tolerance.
- In this context there is a need for adjuvants that enhance the host immune response to a sublingual administration of antigens and help establishing T-cell mediated active tolerance mechanisms.
- Immunostimulatory agents or adjuvants have been used for many years to improve the host immune responses to, for example, vaccines.
- A wide range of adjuvants can provoke potent immune responses to antigens but are not deprived of toxic effects. These include saponins complexed to membrane protein antigens (immune stimulating complexes), pluronic polymers with mineral oil, killed mycobacteria in mineral oil, Freund's complete adjuvant, bacterial products, such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as lipid A, and liposomes.
- Various safer adjuvants have been proposed. For instance, Lactobacillus plantarum was tested for intranasal delivery of heterologous antigens (Grangette et al., (2001) Infection and Immunity 69(3) 1547-1553).
- All these adjuvants have been used with the aim to trigger T-cell mediated immune effector mechanisms (so called Th1 and/or Th2 responses).
- The inventors have now identified adjuvants that elicit antigen-specific regulatory T cells when administered by sublingual, perlingual or oral route.
- These T-cell mediated regulatory mechanisms inhibit the above mentioned Th1 and Th2 effector mechanisms, in particular by eliciting an increase in IL10 secretion by T cells.
- Such adjuvants are of great interest in immunotherapy of allergic, and other immune disorders.
- Although both anergy and T cell depletion are known to contribute to the establishment of peripheral tolerance against self and non-self antigens or environmental allergens, it is now broadly admitted that antigen-specific T cell populations with suppressive/regulatory function play a key role in controlling Immune responses to both self and non-self antigens. These cells, termed regulatory T cells, are heterogeneous, and include both: (i) naturally occurring CD4+CD25+ T cells (ii) cells induced in the periphery following antigen exposure (e.g. Tr1 cells, Th3 cells, and CD8+ TR cells).
- The adjuvants identified by the inventors are a bacterium selected from a Bifidobacterium and a lactic acid bacterium, and a combination of a corticosteroid and vitamin D3 (or its metabolites, such as 1α,25-dihydroxyvitamin D3, or analogs).
- The inventors have notably shown that these adjuvants were liable to induce the secretion of IL10 by human T cells in vitro and that they could improve the clinical efficacy of specific immunotherapy in an animal model of asthma.
- A subject of the invention is thus an immunogenic composition for inducing antigen-specific tolerance for sublingual, perlingual or oral administration, comprising at least an antigen and at least an adjuvant that is;
-
- a lactic acid bacterium, and/or
- a combination of a corticosteroid with vitamin D3 or any metabolite or analog of the latter,
in a pharmaceutically acceptable carrier that is suitable for sublingual, perlingual or oral administration. The preferred route of administration is the perlingual route.
- The invention further provides a kit comprising:
-
- in a first container, at least an antigen;
- in a second container, at least an adjuvant that is a lactobacillus bacterium, and/or a combination of a corticosteroid with vitamin D3 or any metabolite or analog of the latter;
said antigen and said adjuvant being in pharmaceutically acceptable carriers suitable for sublingual, perlingual or oral co-administration.
- These adjuvants are useful for the preparation of an immunogenic composition for sublingual, perlingual or oral administration in association with at least an antigen, for inducing an antigen-specific tolerance, especially for eliciting or improving antigen-specific regulatory T cell responses, in particular by eliciting an increase in IL10 secretion by T cells.
- The immunogenic composition that comprises an antigen and such adjuvant is particularly useful for the preparation of a medicament for treating an allergy, an auto-immune disease, or for preventing graft rejection.
- In one embodiment, the adjuvant is a bacterium selected from a Bifidobacterium and a lactic acid bacterium.
- Preferably, the bacterium selected from a Bifidobacterium and a lactic acid bacterium is a probiotic.
- The term “probiotic” relates to bacteria which exert a beneficial effect on a host they are intended to be administered to, by improving the equilibrium of the intestinal flora of said host.
- Bifidobacteria include those belonging to the genus Bifidibacterium, such as Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium infantis and Bifidobacterium animalis.
- Lactic acid bacteria include those belonging to the genus Lactobacillus, Lactococcus or Streptococcus, such as Lactobacillus plantarum, Lactobacillus delbrueckii, Lactobacillus acidophilus, Lactobacillus fermentum, Lactobacillus casei, Lactobacillus rhamnosus, Lactococcus lactis and Streptococcus thermophilus.
- The adjuvant may further be a mixture of at least two bacteria selected from Bifidobacteria and a lactic acid bacteria, in particular at least two lactic acid bacteria, of different genus or species. It may also be one or several mutants thereof, selected for specific immunomodulatory properties.
- Preferably the bacteria selected from a Bifidobacterium and a lactic acid bacterium, in particular the lactic acid bacterium, is liable to induce IL10 production by T cells.
- More preferably, the lactic acid bacterium is a Lactobacillus, most preferably Lactobacillus plantarum.
- The bacteria selected from a Bifidobacterium and a lactic acid bacterium, in particular the lactic acid bacterium, may be present in the immunogenic composition of the invention at about 1.108 to 1.109 colony forming units (CFU)/ml, preferably about 5.108 to 1.109 CFU/ml.
- In another embodiment, the adjuvant is a combination of a corticosteroid with vitamin D3 or any metabolite or analog of the latter. Preferably the adjuvant is a combination of (i) a corticosteroid and (ii) vitamin D3 or 1α,25-dihydroxyvitamin D3.
- The glucocorticoid used as an adjuvant may be of any type. It may be selected from the group consisting of cortisone, hydrocortisone, beclomethasone, flunisolide, prednisone, prednisolone, methylprednisolone, triamcinolone, deflazacort, betamethasone, dexamethasone, diflorasone, fluticasone, halobetasol, budesonide, clobetasol, fluocinolone, and triamcinolone, or any pharmaceutically acceptable salt thereof. Preferably it is dexamethasone or fluticasone. Most preferably it is dexamethasone.
- As used herein the term “vitamin D3” means cholecalciferol. Its metabolites or analogs include 1α,25-dihydroxyvitamin D3 and any of cholecalciferol;
- 1α,25-dihydroxy-26,27-hexafluorocholecalciferol;
- 1α,25-dihydroxy-22-ene-26,27-hexafluorocholecalciferol;
- 1α,25-dihydroxy-26,27-hexafluoro-16-ene-23-yne-cholecalciferol;
- 1α,25-dihydroxy-23-yne-cholecalciferol;
- 1α,25-dihydroxy-16-ene-cholecalciferol;
- 1α,25-dihydroxy-16-ene-23-yne-cholecalciferol;
- 26,26,26,27,27,27-hexafluoro-1α-fluoro-25-hydroxy-16-ene-23-yne-cholecalciferol;
- 26,26,26,27,27,27-hexafluoro-1α-25-dihydroxy-16-ene-23-yne-19-nor-cholecalciferol;
- 26,26,26,27,27,27-hexafluoro-25-hydroxy-16-ene-23-yne-19-nor-cholecalciferol; and
- 26,26,26,27,27,27-hexafluoro-1α-fluoro-25-hydroxy-16-ene-23-yne-19-nor-cholecalciferol.
- A preferred combination is dexamethasone and 1α,25-dihydroxyvitamin D3.
- In a particular embodiment, the combination of vitamin D3 or its metabolites or analogs, and corticosteroid, may be present in the following proportions:
-
- vitamin D3 (or its metabolites or analogs)/corticosteroid: 0.001 to 0.01%, preferably about 0.003% (w/w);
- adjuvant (vitamin D3 or its metabolites or analogs+corticosteroid)/antigen: 1 to 10%, preferably about 4% (w/w);
- adjuvant (vitamin D3 or its metabolites or analogs+corticosteroid)/whole composition: 1 to 10%, preferably about 3 to 5%, preferably about 4% (w/w).
- The antigen may of any type. It can be a protein, a polypeptide or a peptide, a carbohydrate, a lipid, or a nucleic acid.
- Peptides having defined amino acid sequences and which comprise T cell epitopes, may be identified for any protein antigen or autoantigen. One method includes dividing the protein antigen into non-overlapping, or overlapping peptides of desired lengths and synthesizing, purifying and testing those peptides to determine whether the peptides comprise at least one T cell epitope using any number of assays, (e.g. T cell proliferation assays, lymphokine secretion assays, and T cell non-responsiveness studies). In another method an algorithm is used for predicting those peptides which are likely to comprise T cell epitopes and then synthesizing, purifying and testing the peptides predicted by the algorithm in T cell assays to determine if such predicted peptides cause T cell proliferation or lymphokine secretion, or T cell non-responsiveness and are therefore likely to contain T cell epitopes.
- In a preferred embodiment, the antigen is an allergen. An “allergen” is defined as a substance, usually a protein, which elicits the production of IgE antibodies in predisposed individuals. Similar definitions are presented in the following references: Clin. Exp. Allergy, No. 26, pp. 494-516 (1996); Mol. Biol. of Allergy and Immunology, ed. R. Bush, Immunology and Allergy Clinics of North American Series (August 1996).
- Preferably the antigen is a protein allergen, which means any amino acid chain likely to trigger an allergic response, including short peptides of about 6 to 20 aminoacids, polypeptides, or full proteins.
- Preferably the protein allergen is selected from the group consisting of a protein allergen of the genus Dermatophagoides; a protein allergen of the genus Felis; a protein allergen of the genus Ambrosia; a protein allergen of the genus Lolium; a protein allergen of the genus Cryptomeria; a protein allergen of the genus Alternaria; a protein allergen of the genus Alder; a protein allergen of the genus Betula; a protein allergen of the genus of Blomia; a protein allergen of the genus Quercus; a protein allergen of the genus Olea; a protein allergen of the genus Artemisia; a protein allergen of the genus Plantago; a protein allergen of the genus Parietaria; a protein allergen of the genus Canine; a protein allergen of the genus Blattella; a protein allergen of the genus Apis; a protein allergen of the genus Cupressus; a protein allergen of the genus Thuya; a protein allergen of the genus Chamaecyparis; a protein allergen of the genus Periplaneta; a protein allergen of the genus Agropyron; a protein allergen of the genus Secale; a protein allergen of the genus Triticum; a protein allergen of the genus Cynorhodon; a protein allergen of the genus Juniperus; a protein allergen of the genus Dactylis; a protein allergen of the genus Festuca; a protein allergen of the genus Poa; a protein allergen of the genus Avena; a protein allergen of the genus Holcus; a protein allergen of the genus Anthoxanthum; a protein allergen of the genus Arrhenatherum; a protein allergen of the genus Agrostis; a protein allergen of the genus Phleum; a protein allergen of the genus Phalaris; a protein allergen of the genus Paspalum; and a protein allergen of the genus Sorghum.
- Examples of various known protein allergens derived from some of the above-identified genus include: Betula (verrucosa) Bet v I; Bet v II; Blomia Blo t I; Blo t III; Blo t V; Blo t XII; Cynorhodon Cyn d I; Dermatophagoides (pteronyssinus or farinae) Der p I; Der p II; Der p III; Der p VII; Der f I; Der f II; Der f III; Der f VII; Felis (domesticus) Fel d I; Ambrosia (artemiisfolia) Amb a I.1; Amb a I.2; Amb a I.3; Amb a I.4; Amb a II; Lollium (perenne) Lol p I; Lot p II; Lol p III; Lot p IV; Lol p IX (Lol p V or Lol p Ib); Cryptomeria (japonica) Cry j I; Cry j II; Can f I; Can f II; Juniperus (sabinoides or virginiana) Jun s I; Jun v I; Juniperus (ashei) Jun a I; Jun a II; Dactylis (glomerata) Dac g I; Dac g V; Poa (pretensis) Poa p I; Phi p I; Phl p V; Phi p VI and Sorghum (halepensis) Sor h I.
- In addition, similar to allergy, autoimmune diseases such as Type I diabetes, multiple sclerosis, and rheumatoid arthritis are generally accepted as being the result of an antigen specific T cell mediated response against an antigen which in the case of autoimmune disease is an autoantigen, i.e. an antigen that belongs to the body's own tissue. The same applies to the phenomenon of graft rejection, where the antigen belongs to the graft tissue, possibly coming from another individual or even from another animal species.
- In another embodiment, the antigen is involved in a autoimmune disease or graft rejection.
- A number of antigens (i.e. autoantigens) have been found to cause symptoms in autoimmune diseases (i.e. autoantigens such as insulin; myelin basic protein; rh factor; acetylcholine receptors; thyroid cell receptors; basement membrane proteins; thyroid proteins, ICA-69 (PM-1); glutamic acid decarboxylase (64K or 65 K); proteolipid protein (PLP), myelin associated glycoprotein (MAG), Collagen (Type II), Heat Shock Protein and carboxypeptidase H) such as diabetes, rheumatoid arthritis, and multiple sclerosis.
- The antigen and the adjuvant as above defined are either combined in an immunogenic composition or are presented separately, for a co-administration.
- One may employ one or several antigens. The immunogenic composition comprises at least an adjuvant as defined above, that is to say that one may also employ additional adjuvants.
- The antigen and the adjuvant are associated with a pharmaceutically acceptable carrier that is suitable for sublingual, perlingual (i.e. through the tongue mucosa) or oral administration. The antigen and the adjuvant can also be co-administered in the form of separate compositions. The co-administration means either simultaneous or consecutive administration of said compositions.
- As used herein, the term “pharmaceutically acceptable carrier” includes solvents, dispersion media, coatings, isotonic and absorption delaying agents, mucoadhesive excipients, and the like, that do not produce an adverse or other untoward reaction when administered to an animal, or a human, as appropriate.
- Preferred sublingual, perlingual or oral dosage forms include solid forms, adhesive tablets, biofilms or creams, ointments, powders, gels; and pastes. A preferred form is a tablet, e g., as those described in U.S. Pat. No. 5,244,663. The sublingual or perlingual dosage unit is manufactured to disintegrate rapidly. The time period for complete disintegration of the dosage unit is typically in the range of from about 10 seconds to about 30 minutes, and optimally is less than 5 minutes.
- Carriers may further include, but are not limited to disintegrants, binders, lubricants, flavoring, colorants, preservatives. Suitable disintegrants include dry starch, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, stearic monoglyceride, lactose, as well as cross-linked polyvinylpyrrolidones, such as crospovidone (e.g., Polyplasdone™. XL, which may be obtained from GAF), cross-linked carboxylic methylcelluloses, such as croscarmelose (e.g., Ac-di-sol™, which may be obtained from FMC), alginic acid, and sodium carboxymethyl starches (e.g., Explotab™, which may be obtained from Edward Medell Co., Inc.), methylcellulose, agar bentonite and alginic acid. Binders, if used, are those that enhance adhesion. Examples of such binders include, but are not limited to, starch, gelatin and sugars such as sucrose, dextrose, molasses, and lactose. Preferred lubricants are stearates and stearic acid.
- Lactose, mannitol, and croscarmelose are preferred excipients.
- Additional components that may be incorporated into the dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington; The Science and Practice of Pharmacy, 19th edition (Mack Publishing, 1995).
- In another embodiment the immunogenic composition is in a liquid form.
- The composition can be administered as dry powder particles or as an atomized aqueous solution suspended in a carrier gas (e.g. air or N2). Preferred aerosol formulations may comprise for example, a physiologically-acceptable buffered saline solution containing between about 1 μg and about 300 μg of the antigens.
- For the preparation of aqueous suspensions and/or elixirs, one may employ various sweetening or flavouring agents, colouring matter and, if so desired, emulsifying and/or suspending agents, together with such diluents as water, ethanol, propylene glycol, glycerine and various combinations thereof. Glycerine is preferred.
- The immunogenic composition is preferably administered to the patient under the tongue. The sublingual mucosa, located on the underside of the tongue, facilitates capture of the antigen and adjuvant by Langerhans-like cells that migrate to draining lymph nodes to prime T lymphocytes.
- For example, recombinant Bet v I protein allergen has been formulated as a tablet for sublingual administration.
- When it is in liquid form, the composition can be administered under the tongue by placing one or more drops underneath the tongue or by spraying the underside of the tongue with a preselected volume of the liquid composition. Preferably, the administered volume, either drops or spray, is less than about 1 ml.
- A route of administration of particular interest is to keep the composition under the tongue a few minutes, e.g. about 2 minutes, before swallowing it.
- The present invention further provides a kit comprising:
-
- in a first container, at least an antigen;
- in a second container, at least an adjuvant that is a lactic acid bacterium,
said antigen and said adjuvant being in pharmaceutically acceptable carriers suitable for sublingual, perlingual or oral co-administration.
- Another subject of the invention is a kit comprising:
-
- in a first container, at least an antigen;
- in a second container a corticosteroid in a third container, vitamin D3 or any metabolite or analog of the latter;
each being in pharmaceutically acceptable carriers suitable for sublingual, perlingual or oral co-administration
- A further subject of the invention is a kit comprising:
-
- in a first container, at least an antigen;
- in a second container a combination of a corticosteroid and vitamin D3 or any metabolite or analog of the latter;
each being in pharmaceutically acceptable carriers suitable for sublingual, perlingual or oral co-administration.
- When the antigen and the adjuvant are co-administered in separate compositions or provided as a kit, they can be in different types of carriers, both suitable for sublingual, perlingual or co-administration. For instance, the antigen may be in the form of a solid composition, while the adjuvant is in a liquid composition.
- The association of an antigen with the adjuvant as defined above elicits or improves antigen-specific regulatory T cell responses.
- The immunogenic compositions that combine an antigen with the adjuvant can be used as a vaccine, or in a therapeutic or prophylactic treatment regimen for the prevention of, or delay in, the onset of disease symptoms caused by an offending antigen or results in reduction, progression, or alleviation of symptoms caused by an offending antigen, i.e. down regulation of an antigen specific immune response. The kits disclosed herein are similarly useful.
- Immunotherapy of allergies generally comprises desensitization or hyposensitisation, which is a treatment consisting in administering to the patient progressively increasing doses of the allergen(s) to which the patient has developed or is likely to develop a sensitivity.
- It is further provided a method for preventing or treating an allergy, which method comprises administering to a subject in need thereof an antigen and the adjuvant as described above, e.g. in the form of an immunogenic composition, wherein the antigen is an allergen.
- It is further provided a method for treating a autoimmune disease, which method comprises administering to a subject in need thereof an antigen and the adjuvant as described above, e.g. in the form of an immunogenic composition, e, wherein the antigen is involved in the autoimmune disease. Non limiting examples include rheumatoid arthritis, multiple sclerosis, endocrine ophthalmopathy, uveoretinitis,
Type 1 diabetes, systemic lupus erythematosus sclerodermia, myasthenia gravis, Grave's disease, glomerulonephritis, autoimmune hematological disorder, autoimmune inflammatory bowel disease, and Crohn's disease. - The antigen and the adjuvant as described above, e.g. in the form of an immunogenic composition, are also useful in the treatment of recipients of tissue or organ transplants to reduce host-induced allograft rejection.
- It is further provided a method for preventing a graft rejection, which method comprises administering to a subject in need thereof an antigen and the adjuvant as described above, e.g. in the form of an immunogenic composition, wherein the antigen belongs to the graft tissue and is likely to cause graft rejection.
- The subject is preferably a human, regardless of the age, sex, and condition. It may also be any other mammal, including pets such as cats or dogs.
- The example and figures below illustrate the invention without limiting its scope,
-
FIG. 1 : Experimental design - A. Sensitization was performed by two intraperitoneal (i.p.) injections in 14 days interval with 10 μg ovalbumin (OVA) or phosphate buffer saline (PBS) (control) adsorbed to 2 mg Al(OH)3. The sensitization was followed by a 20 min aerosol challenge with 1% w/v OVA on 5 consecutive days. Blood samples (bleeding) were taken in order to perform the anti-OVA antibody titration. Measurements of airway responsiveness were performed by whole body plethysmography. After sacrifice of mice, spleen cells and lung were isolated for cytokine analysis and inflammation detection respectively.
- For tolerance induction in a therapeutic model, sensitized mice were sublingually treated with PBS (control), OVA or OVA plus adjuvant every week, twice a week, during 2 months at a concentration of 500 μg. Blood samples (bleeding) were taken for humoral response analysis. Measurements of airway responsiveness were performed by whole body plethysmography. After sacrifice of mice, spleen and lung were removed for in vitro cytokine assays and inflammation analysis respectively.
- B. For tolerance induction in a prophylactic model, mice were sublingually treated with PBS, OVA or OVA plus adjuvant every week, twice a week, during 1 month at a concentration of 500 μg. Sensitization was performed by two intraperitoneal (i.p.) injections in 14 days interval with 10 μg ovalbumin (OVA) or phosphate buffer saline (PBS) (control) adsorbed to 2 mg Al(OH)3. The sensitization was followed by a 20 min aerosol challenge with 1% w/v OVA on 5 consecutive days. Blood samples (bleeding) were taken for humoral response analysis. Measurements of airway responsiveness were performed by whole body plethysmography. After sacrifice of mice, spleen and lung were removed for in vitro cytokine assays and inflammation analysis respectively.
-
FIG. 2 : Humoral, cellular, respiratory responses, and inflammation after sensitization - A. OVA-specific IgG1 and IgG2a (
dilution 1/100) antibody levels were measured in sera from 4 mice sensitized with OVA. - B. OVA-specific IgE (
dilution 1/10) antibody level was measured in sera from 3 mice sensitized with OVA. - C. IFN-γ, IL-5 and IL10 levels in spleen cell of mice sensitized with OVA were measured by Elispot.
- D. The airway responsiveness was determined for sensitized mice with PBS or OVA by measurement of Penh index in response to methacholine (50 mg/ml). Eight mice per group were displayed (▴=mean).
- E. Representative lung sections obtained 48 h after the last challenge. Paraffin tissue sections were stained with HES (Hematoxylin, eosin, safran). One arrow (top) indicates bronchial mucus secretion and the other arrow (bottom) indicates specific cellular infiltration.
-
FIG. 3 : Airway responsiveness after tolerization - The airway responsiveness was determined for healthy mice, mice sensitized with OVA and tolerized with PBS, mice sensitized with OVA and tolerized with OVA and mice sensitized with OVA and tolerized with OVA+dexamethasone (Dex)+1α,25-dihydroxyvitamin D3 (vitD3) (panel A) or OVA+L. plantarum (panel B) by measurement of Penh value in response to methacholine (50 mg/ml). Four to eight mice per group were displayed (horizontal bar median).
-
FIG. 4 : TGF-β production after tolerization - TGF-β production was determined for mice sensitized with OVA and tolerized with PBS (n=2), mice sensitized with OVA and tolerized with OVA (n=3) and mice sensitized with OVA and tolerized with OVA+VitD3+Dex (n=4 (panel A) or OVA+L. plantarum (n=3) (panel B) by Elipsot.
- Summary:
- Adjuvants inducing IL10 gene expression by human T cells in vitro (Lactobacillus plantarum or 1α,25-dihydroxyvitamin D3+dexamethasone) were mixed with ovalbumin and administered sublingually to Balb/c mice sensitized to ovalbumin. When compared with ovalbumin alone or untreated animals, each of those adjuvants could enhance the clinical efficacy of the vaccine (based on improvement of the respiratory function). Clinical improvement was correlated with an increase in ovalbumin-specific TGFβ producing T lymphocytes in the spleen (i.e. T cells with a regulatory profile, subtype Tr1 or Th3).
- Materials and Methods:
- 1. Animals, Culture Medium, Reagents and Antigens
- Six-week-old female BALB/c mice were purchased from Charles River (L'Arbresle, France) and maintained on an ovalbumin-free diet. Each experimental group consisted of two to eight mice. The international levels of ethical standards for the use of animals were applied.
- Culture medium for spleen cell consisted of RPMI 1640 containing 10% fetal calf serum and 1% L-glutamine (all from Invitrogen, France).
- Ovalbumin (OVA, Garde V) was purchased from Sigma Chemicals. Phosphate-buffer saline (PBS) and alum were purchased from Invitrogen (France) and Pierce (Rockford, Ill.), respectively.
- 2. Adjuvants
- A strain of lactic acid bacteria (LAB), Lactobacillus plantarum, was used for in vivo applications in BALB/c mice (Microbiologics, Inc., Saint Cloud) at 2.108 colony forming units (CFU)/ml in sterile PBS.
- 1α,25-dihydroxyvitamin D3 (1 mg/kg) and dexamethasone (0.03 μg/kg) in sterile PBS were also used.
- 3. Mice Sensitization and Tolerization (
FIG. 1 ) - Sensitization was performed by two intraperitoneal (i.p.) injections in 14 days interval with 10 μg OVA adsorbed to 2 mg Al(OH)3 in a total volume of 100 μl. The sensitization was followed by a 20 min aerosol challenge with 1% w/v OVA on 5 consecutive days with an aerosol delivery system (Buxco Europe; Ltd, UK). Control animals were sham treated with sterile PBS.
- For tolerance induction in a therapeutic model, sensitized mice were sublingually treated with OVA or OVA plus adjuvant every week, twice a week, during 2 months at a concentration of 500 μg (20 μl). Control mice were sensitized with OVA followed by sham tolerization with PBS.
- For tolerance induction in a prophylactic model, mice were sublingualy treated with PBS, OVA or OVA plus adjuvant every week, twice a week, during 1 month at a concentration of 500 μg. Sensitization was performed by two intraperitoneal. (i.p.) injections in 14 days interval with 10 μg ovalbumin (OVA) or phosphate buffer saline (PBS) (control) adsorbed to 2 mg Al(OH)3. The sensitization was followed by a 20 min aerosol challenge with 1% w/v OVA on 5 consecutive days
- 4. Determination of Airway Responsiveness
- Measurements of airway responsiveness were performed by whole body plethysmography (Buxco Europe; Ltd, UK). Airflow signals were recorded in response to aerosolized methacholine (50 mg/ml), 1 minute, four times. The higher value of Penh (enhanced pause) was taken into account for the calculation of the Penh index (Penh index=Penh measured/Penh PBS).
- 5. Determination of Serum Allergen-Specific Antibody Levels
- Blood samples were collected after the sensitization in order to perform the anti-OVA antibody titration by ELISA. For detection of IgG1 and IgG2a antibodies, the mouse anti-serum was incubated with purified OVA (0.1 μg) coated onto ELISA plates (Nunc, Denmark). Biotinylated-rat anti-mouse IgG1 or IgG2a antibodies (
dilution 1/100, BD Pharmingen) were applied and streptavidine-peroxidase-conjugated rat anti-mouse IgG antibodies (dilution 1/400, BD Pharmigen) were used for detection. An o-phenylene diamine and hydrogen peroxyde substrate (Sigma) was added, the reaction stopped and the optic density (OD) read using an ELISA reader at 492 nm. - For detection of IgE antibody; mouse IgE antibodies (Bethyl laboratories) were coated onto Elisa plates. The mouse anti-serum was applied and OVA-digoxigenin (
dilution 1/20, Roche) plus HRPO-conjugated rabbit anti-digoxigenin (dilution 1/1000, Roche) were used for detection. An ABTS substrate was added (Roche), the reaction stopped and the OD read using an ELISA reader at 405 nm. - 6. Dosage of TGF-β
- Dosage of TGF-β from supernatants of spleen cell cultures was performed with an ELISA kit (R&D systems).
- 7. Spleen Cell Cultures for Cytokine Analysis by Elispot
- Mice were killed by cervical dislocation. Spleen cells were isolated and plated in triplicate in 96-well flat-bottomed ELISPOT plates (Millipore, Mass.) at densities of 2×105 cells per well. Different conditions were used: medium alone, OVA (100 μg/ml) and PMA (phorbol myristyl acetate) (50 ng/ml, Sigma)/ionomycine (500 ng/ml, Sigma) which was used as positive control. Spot forming cells (SFCs) were monitored for IFN-γ, IL-5 and IL10. Elispot kits were from R&D systems Europe.
- 8. Lung Histology
- Mice were killed by cervical dislocation. Lung were isolated and embedded in paraffin. Micrometer paraffin sections were stained with HES (hematoxylin, eosin, safran).
- 9. Gene Expression by Human T Cells
- Dendritic cells (DC) were treated with candidate adjuvants for 24 h, washed and cultured with purified allogenic naïve CD4+ T cells. mRNAs were extracted 24 h to 5 days later and gene expression was assessed by quantitative PCR with primers specific for the tested genes. Only data above 2 fold increase were considered as significant.
- Results
- A. Selection of IL-10-Inducing Adjuvants in Human In Vitro Model
- Human in vitro model consisting in coculture of human preated DC with allogenic T cells have been used to select IL10-inducing adjuvants. Briefly, human DC were treated with adjuvants. After 24 h, DC were washed and cultured with allogenic naïve CD4+ T cells. After 24 h to 5 days, gene expression in human T cells was assessed by quantitative PCR.
- Among several putative adjuvants tested, Lactobacillus plantarum and 1α,25-dihydroxyvitamin D3 in combination with dexamethasone (Vit/Dex) have been shown liable to induce IL10 gene expression by human T cells in vitro (Table 1).
-
TABLE 1 Summary of screening data for IL10 inducing adjuvants Gene expression by T cells Adjuvants Tbet IFN GATA3 Foxp3 TGF IL10 Vit/Dex − − + + + +++ L. plantarum − +++ − − − ++ R848 − + − − − − LTA − ++ − − − − Pam3CSK4 − − − − − − LPS pg − − − − − − Imiquimod − − + − + − ssPolyU − − − − − − - B. Immunotherapy Experiments
- 1. Murine Models of Sensitization with OVA
- Mice, immunized i.p. with OVA absorbed to Al(OH)3 and subsequently exposed to an OVA solution via aerosol, were analysed for their humoral, cellular, respiratory responses and inflammation. The sensitization procedure has been shown to induce OVA-specific IgG1 and IgE, but little IgG2a antibodies in serum (
FIGS. 2A and 2B ). In accordance with the production of allergen-specific IgE antibodies, spleen cells from the OVA-sensitization mice displayed strong Th2 profile in response to OVA (FIG. 2C ). OVA-sensitized mice present airway hyperresponsiveness to methacholine when compared to PBS-treated mice (FIG. 2D ). Finally, the sensitization protocol has been shown to induce specific cellular infiltration of the lung and bronchial mucus secretion (FIG. 2E ). - 2. Sublingual Tolerization in a Therapeutic Model of Type I Allergy
- After having sensitized the mice, the inventors have tested different protocol of tolerization and particularly the capacity of candidate adjuvants to upregulate antigen-specific regulatory T cell responses and accelerate the tolerance induction by sublingual way. Lactobacillus plantarum and 1α,25-dihydroxyvitamin D3 in combination with dexamethasone have been tested as adjuvants for upregulation of antigen-specific regulatory T cell responses.
- Sublingual treatment with OVA administered together with L. plantarum (
FIG. 3A ) or 1α,25-dihydroxyvitamin D3 plus dexamethasone (FIG. 3B ) led to a reduction of airway responsiveness as compared to PBS-treated mice or animals treated with OVA alone. - Finally, TGF-β production was enhanced in supernatant of spleen cell cultures of mice treated with OVA and L. plantarum (
FIG. 4A ) or 1α,25-dihydroxyvitamin D3 plus dexamethasone (FIG. 4B ) compared to PBS-treated mice or animals treated with OVA alone. - 3. Sublingual Tolerization in a Prophylactic Model of Type I Allergy
- Sublingual desensitization is also tested in a murine prophylactic model of asthma. Briefly, Balb/c mice are sublingually administered with an adjuvant to be tested (1α,25-dihydroxyvitamin D3+dexamethasone) in association with an antigen (OVA) (500 μg) 2 times per week during 4 weeks prior to being sensitized and challenged by OVA.
- Results indicate that pre-treatment of mice with OVA+adjuvant according to the invention is liable to induce a reduction of airway responsiveness following subsequent sensitization.
- 4. Murine Models of Sensitization with Birch Pollen and House Dust Mite
- The adjuvants according to the invention are tested in murine model of sensitization either to birch pollen or house dust mite and also seem promising for preventing or treating allergies with these allergens.
Claims (46)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/240,628 US10610586B2 (en) | 2005-05-18 | 2016-08-18 | Compositions for antigen-specific induction of tolerance |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05291073A EP1723965A1 (en) | 2005-05-18 | 2005-05-18 | Compositions for antigen-specific induction of immuno-tolerance via oral immunization |
EP05291073.4 | 2005-05-18 | ||
EP05291073 | 2005-05-18 | ||
PCT/IB2006/001310 WO2006123230A2 (en) | 2005-05-18 | 2006-05-18 | Compositions for antigen-specific induction of immuno-tolerance via oral immunization |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2006/001310 A-371-Of-International WO2006123230A2 (en) | 2005-05-18 | 2006-05-18 | Compositions for antigen-specific induction of immuno-tolerance via oral immunization |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/240,628 Division US10610586B2 (en) | 2005-05-18 | 2016-08-18 | Compositions for antigen-specific induction of tolerance |
US15/240,628 Continuation US10610586B2 (en) | 2005-05-18 | 2016-08-18 | Compositions for antigen-specific induction of tolerance |
Publications (2)
Publication Number | Publication Date |
---|---|
US20080233155A1 true US20080233155A1 (en) | 2008-09-25 |
US9555102B2 US9555102B2 (en) | 2017-01-31 |
Family
ID=34942312
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/914,815 Active 2027-04-21 US9555102B2 (en) | 2005-05-18 | 2006-05-18 | Compositions for antigen-specific induction of tolerance |
US15/240,628 Active 2027-06-18 US10610586B2 (en) | 2005-05-18 | 2016-08-18 | Compositions for antigen-specific induction of tolerance |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/240,628 Active 2027-06-18 US10610586B2 (en) | 2005-05-18 | 2016-08-18 | Compositions for antigen-specific induction of tolerance |
Country Status (4)
Country | Link |
---|---|
US (2) | US9555102B2 (en) |
EP (3) | EP1723965A1 (en) |
ES (2) | ES2731849T3 (en) |
WO (1) | WO2006123230A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110097361A1 (en) * | 2008-02-01 | 2011-04-28 | Mimi Lai-Kuan Tang | Method of inducing tolerance to an allergen |
US20150147388A1 (en) * | 2011-06-23 | 2015-05-28 | University Of Florida Research Foundation, Inc. | Materials and Methods for Modulating immune Responses |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
US11505581B2 (en) * | 2015-05-14 | 2022-11-22 | La Jolla Institute For Allergy And Immunology | Antigens and T cell epitopes from cockroach and methods of making and using same |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090169582A1 (en) * | 2006-04-20 | 2009-07-02 | National University Of Singapore | Recombinant lactobacillus and use of the same |
CN103263443B (en) | 2007-12-07 | 2016-09-14 | 努特里希亚公司 | Bacillus bifidus for dust mite allergy |
PL217128B1 (en) | 2010-08-02 | 2014-06-30 | Inst Biochemii I Biofizyki Polskiej Akademii Nauk | Synthetic genes encoding peptide fragments of natural myelin proteins intended to evoke the effect of food tolerance, DNA fragments containing these genes, process for the preparation of these peptides in a microbial (bacterial) system and their medical application |
CN105709221B (en) | 2011-04-06 | 2020-11-17 | 拜欧瓦克西姆有限公司 | Pharmaceutical composition for the prevention and/or treatment of HIV diseases in humans |
WO2013104424A1 (en) * | 2012-01-13 | 2013-07-18 | Instytut Biochemii I Biofizyki Pan | Synthetic genes encoding peptide fragments of natural myelin proteins for induction of oral tolerance, dna fragment comprising these genes, means of obtaining these peptides in a microbial (bacterial) system and their medical application |
WO2013107526A2 (en) * | 2012-01-22 | 2013-07-25 | Instytut Biochemii I Biofizyki Pan | Synthetic genes encoding peptide fragments of natural myelin proteins for induction of oral tolerance, dna fragment comprising these genes, means of obtaining these peptides in a microbial (bacterial) system and their medical application |
US10500217B2 (en) | 2018-04-30 | 2019-12-10 | Leslie Ray Matthews, M.D., Llc | Vitamin D3, heat shock proteins, and glutathione for the treatment of chronic inflammation and chronic diseases |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020146429A1 (en) * | 2001-02-07 | 2002-10-10 | Hsu Ching-Hsaing | Live vaccines for allergy treatment |
US20040087018A1 (en) * | 2000-10-04 | 2004-05-06 | Barrat Franck J. | Regulatory T cells; methods |
US20060057154A1 (en) * | 2003-03-28 | 2006-03-16 | Universiteit Utrecht Holding B.V. | Compositions for inducing of immunotolerance |
US20080254058A1 (en) * | 2004-12-14 | 2008-10-16 | Alk-Abello A/S | Pharmaceutical Composition Comprising a Bacterial Cell Displaying a Heterologous Proteinaceous Compound |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5244663A (en) | 1987-01-28 | 1993-09-14 | Medibrevex | Therapeutic method against allergy |
JPH07106142B2 (en) | 1989-04-21 | 1995-11-15 | 株式会社ヤクルト本社 | Bifidobacterium longum or Bifidobacterium breve capable of inducing IgA |
JP2796635B2 (en) * | 1989-10-04 | 1998-09-10 | 雪印乳業株式会社 | Immune enhancer |
JPH0551321A (en) | 1991-08-23 | 1993-03-02 | Yotsuba Nyugyo Kk | Immune activating agent |
US6100388A (en) * | 1998-03-16 | 2000-08-08 | Biogaia Biologies Ab | Lactobacilli harboring aggregation gene as a vaccine delivery vehicle |
EP1084709A1 (en) * | 1999-09-17 | 2001-03-21 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Oral recombinant lactobacilli vaccines |
HU227086B1 (en) * | 1999-11-25 | 2010-06-28 | Vakcina Kft | Lactobacillus vaccine for treating prostata inflammatory and benign prostata hyperplasia |
US7655248B2 (en) | 2000-06-19 | 2010-02-02 | Hunter Immunology Limited | Compositions and methods for treatment of candidiasis |
EP1184709B1 (en) | 2000-07-31 | 2003-12-10 | M.M. Evolution S.R.L. | Spectacle-frame |
JP2002281966A (en) * | 2001-03-26 | 2002-10-02 | Japan Science & Technology Corp | Transformed lactobacillus obtained by allergen gene |
WO2003063786A2 (en) * | 2002-01-31 | 2003-08-07 | Symbigene, Inc. | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
CA2539708A1 (en) | 2003-09-24 | 2005-04-07 | Bioxell S.P.A. | 1,3-diaclyated,26,27-alkyl/haloalkyl vitamin d3 compounds and methods of use thereof |
-
2005
- 2005-05-18 EP EP05291073A patent/EP1723965A1/en not_active Withdrawn
-
2006
- 2006-05-18 EP EP06755894.0A patent/EP1881846B1/en active Active
- 2006-05-18 EP EP16181540.2A patent/EP3213767B1/en active Active
- 2006-05-18 ES ES06755894T patent/ES2731849T3/en active Active
- 2006-05-18 ES ES16181540T patent/ES2924990T3/en active Active
- 2006-05-18 US US11/914,815 patent/US9555102B2/en active Active
- 2006-05-18 WO PCT/IB2006/001310 patent/WO2006123230A2/en not_active Application Discontinuation
-
2016
- 2016-08-18 US US15/240,628 patent/US10610586B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040087018A1 (en) * | 2000-10-04 | 2004-05-06 | Barrat Franck J. | Regulatory T cells; methods |
US20020146429A1 (en) * | 2001-02-07 | 2002-10-10 | Hsu Ching-Hsaing | Live vaccines for allergy treatment |
US7060687B2 (en) * | 2001-02-07 | 2006-06-13 | Genmont Biotechnology Co. | Live vaccines for allergy treatment |
US20060057154A1 (en) * | 2003-03-28 | 2006-03-16 | Universiteit Utrecht Holding B.V. | Compositions for inducing of immunotolerance |
US20080254058A1 (en) * | 2004-12-14 | 2008-10-16 | Alk-Abello A/S | Pharmaceutical Composition Comprising a Bacterial Cell Displaying a Heterologous Proteinaceous Compound |
Non-Patent Citations (4)
Title |
---|
Detmer et al. 'Live bacterial vaccines â a review and identification of potential hazards.' Microbial Cell Factories 5:23, pages 1-12, 2006. * |
Hols et al. 'Efficient secretion of the model antigen M6-gp41 E in Lactobacillus plantarum NCIMB 8826.' Microbiol. 143, 2733-2741, 1997. * |
Repa et al. 'Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy.' Vaccine 22:87-95, 2003. * |
van Overveldt et al. 'IL-10-Inducing Adjuvants Enhance Sublingual Immunotherapy Efficacy in a Murine Asthma Model.' Allerg. Immunol. 145:152-162, 2008. * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110097361A1 (en) * | 2008-02-01 | 2011-04-28 | Mimi Lai-Kuan Tang | Method of inducing tolerance to an allergen |
US9402896B2 (en) * | 2008-02-01 | 2016-08-02 | Murdoch Childrens Research Institute | Method of inducing tolerance to an allergen |
US10071157B2 (en) | 2008-02-01 | 2018-09-11 | Murdoch Childrens Research Institute | Method of inducing tolerance to an allergen |
US20190070288A1 (en) * | 2008-02-01 | 2019-03-07 | Murdoch Childrens Research Institute | Method of inducing tolerance to an allergen |
US20150147388A1 (en) * | 2011-06-23 | 2015-05-28 | University Of Florida Research Foundation, Inc. | Materials and Methods for Modulating immune Responses |
US10022440B2 (en) * | 2011-06-23 | 2018-07-17 | University Of Florida Research Foundation, Incorporated | Materials and methods for modulating immune responses |
US11505581B2 (en) * | 2015-05-14 | 2022-11-22 | La Jolla Institute For Allergy And Immunology | Antigens and T cell epitopes from cockroach and methods of making and using same |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
US11304961B2 (en) | 2017-12-18 | 2022-04-19 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
Also Published As
Publication number | Publication date |
---|---|
WO2006123230A2 (en) | 2006-11-23 |
EP3213767A1 (en) | 2017-09-06 |
WO2006123230A8 (en) | 2009-05-14 |
US20170043013A1 (en) | 2017-02-16 |
US9555102B2 (en) | 2017-01-31 |
EP1881846A2 (en) | 2008-01-30 |
ES2731849T3 (en) | 2019-11-19 |
EP3213767B1 (en) | 2022-07-20 |
ES2924990T3 (en) | 2022-10-13 |
EP1881846B1 (en) | 2019-03-20 |
WO2006123230A3 (en) | 2007-03-15 |
US10610586B2 (en) | 2020-04-07 |
EP1723965A1 (en) | 2006-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10610586B2 (en) | Compositions for antigen-specific induction of tolerance | |
US10668136B2 (en) | Treatment of immune disease by mucosal delivery of antigens using genetically modified Lactococcus | |
US10195269B2 (en) | Induction of mucosal tolerance to antigens | |
TWI528971B (en) | Suppression of a hypersensitivity immune response with unrelated antigen derived from allergen source material | |
Frossard et al. | Lymphocytes in Peyer patches regulate clinical tolerance in a murine model of food allergy | |
EP2627354B1 (en) | Suppression of a type 1 hypersensitivity immune response with an unrelated antigen | |
Vidal et al. | Effect of Lactobacillus paracasei NCC2461 on antigen-specific T-cell mediated immune responses in aged mice | |
Srutkova et al. | Exopolysaccharide from Lacticaseibacillus rhamnosus induces IgA production in airways and alleviates allergic airway inflammation in mouse model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: STALLERGENES S.A., FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MOINGEON, PHILIPPE;RAZAFINDRATSITA, ALAIN;VAN OVERTVELT, LAURENCE;REEL/FRAME:020144/0494 Effective date: 20071008 |
|
AS | Assignment |
Owner name: STALLERGENES, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STALLERGENES SA;REEL/FRAME:036840/0541 Effective date: 20150803 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |